Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970768 | 0.99 | PTPN1 (0.66) | PTPN1MEN1KMT2APTPN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2492465 | 0.85 | RAB9A (0.44) | PTPN1MEN1KMT2APTPN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6554324 | 0.85 | PTPN1 (0.53) | PTPN1MEN1KMT2AALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL5168864 | 0.85 | PTPN1 (0.53) | PTPN1MEN1KMT2AALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL2492387 | 0.85 | EPHX1 (0.51) | MEN1KMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL9967270 | 0.85 | RAB9A (0.59) | PTPN1MEN1KMT2APTPN2RAB9A | |
| Hydrochloric Acid SCHEMBL5949556 | 0.84 | LMNA (0.50) | PTPN1MEN1KMT2APTPN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2495339 | 0.84 | PTPN1 (0.49) | PTPN1MEN1KMT2APTPN2ALDH1A1 | |
| SCHEMBL1459729 | 0.84 | PTPN1 (0.54) | PTPN1MEN1KMT2ARAB9ALMNA | |
| SCHEMBL9967272 | 0.84 | RAB9A (0.45) | PTPN1MEN1KMT2APTPN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | claimed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | claimed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | claimed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | claimed |
| US-20180325878-A1 | N-BIARYLAMIDES | BAYER IP GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| US-20120157490-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180325878-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | PTPN1 4850/4885MEN1 2378/4885KMT2A 737/4885 |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | PTPN1 4844/4885MEN1 4500/4885KMT2A 2509/4885 |
| US-20140288118-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | PTPN1 4850/4885MEN1 2378/4885KMT2A 737/4885 |
| US-20120157490-A1 | N-BIARYLAMIDES | GRIN2A, BCHE, ACHE | PTPN1 4614/4885MEN1 3205/4885KMT2A 1435/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | PTPN1 4850/4885MEN1 2378/4885KMT2A 737/4885 |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | CHRNA7, CHRNA3, CHRNA2 | PTPN1 4830/4885MEN1 4712/4885KMT2A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.